Open AccessMethotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy
Author(s) -
Dapeng Yu,
Shuisheng Zhang,
Alei Feng,
Dongjuan Xu,
Qingshan Zhu,
Yantao Mao,
Yi Zhao,
Yajuan Lv,
Cuiping Han,
Rujun Liu,
Yuan Tian
Publication year - 2019
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000015582
Subject(s) - medicine , ifosfamide , regimen , osteosarcoma , neutropenia , odds ratio , etoposide , febrile neutropenia , chemotherapy , surgery , oncology , carboplatin , cisplatin , pathology